.Attribute Medication, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of people with HER2+ sophisticated bosom cancer cells and also energetic or steady human brain metastases revealed constant intracranial task as well as wide spread efficacy of T-DXd.